Member Info for Ella10

Does this not apply
All medical devices, including IVDs, custom-made devices and systems or procedure packs must be registered with the MHRA before being placed on the Great Britain market. In Great Britain (England, Wales and Scotland), devices must conform to the UK MDR 2002, the EU MDR (until 30 June 2023), or the EU IVDR (until 30 June 2023) in order to be registered with the MHRA. In addition, devices that have been CE marked under the EU MDD, EU AIMDD or EU IVDD will continue to be accepted on the Great Britain market until 30 June 2023 if their certificates remain valid for the EU market under the transitional arrangements in the EU MDR and EU IVDR

Ie there are other routes to market than MDR 2002?

Hi Andy,
I don't think it can be Kalengwa. I wonder if it's one of these projects CaptainBob mentioned. I suspect it may be a project that we are yet to be informed of.

Is it possible that MHC are using some sort of BREXIT related regulations to allow it to continue using Clarigene.

Again?

Hi Panda,
From the Dec RNS
'Attempts are underway to come to an agreement between the parties to avoid wasting more time'

Hi Longfell,
I think you should have a look at some of the court cases that involved arbitration in Zambia - not a quick process.

As per December's RNS ARC are currently defending to two sets of court cases. From the twitter post yesterday it sounds like the arbitration process for the first court case will start mid March. This can take a long time to resolve. There hasn't been any news on the timetable for the second set of cases.
I realise ARC said these case were likely to be heard in H1 2022 but is this timetable similar to the Scoping Study that was expected H1 2021 and we are still waiting for an update on?

I think EKFs recent acquisition of ADL is relevant here
https://www.ekfdiagnostics.com/acquisition-of-us-based-advanced-diagnostic-laboratory-llc.html

I agree that it is certainly good news - better than I expected. However, I would like to see something convincing for Fairbride.

There were a lot of A warrants that if exercised by around the 7th Jan would have got the holders B warrants. The TR1s that I assume related to the shares quoted the 26th Jan 2021 so it may be that these warrants don't expire until the 26th. I am not sure how many of these were left or who held them. It was directors and management at the time - I suspect MM,MF and HG. We have a warrant block listing so would not receive an RNS for warrants unless from a current director. As far as I could tell there was no new equity, that could be attributed to the warrants from the block listing prior to last week's RNS.
https://www.lse.co.uk/rns/KAV/cln-conversion-and-block-listing-application-wyizd7b3jt6n0or.html

We weren't told our share was impacted so presumably it isn't.

MMP had a date set for commercial production being achieved which has obviously not been met. I assume there will have been an allowance for Covid delaying construction but I also assume that we will have some sort of penalties in the contract. I thought this might have been the additional income shown in the last results.

MMP obviously needed more funds.
https://empressroyalty.com/site/assets/files/6229/emprnr2022-01_manicaincrease.pdf

I hope the delay in news is due to us bringing a fund on board.

https://www.digitaljournal.com/pr/empress-royalty-increases-gold-royalty-on-manica-project

I guess a lack of early Jan update is either due to CBs known tendency to delay any not so positive news or perhaps he is hoping for something concrete that he can can give us to add some weight to Q2 revenue expectations.

Does anyone know how the sequencing contract is structured? There appears to be some sort of daily payment and a per sample payment.

Hi Turtlewax,
Since you appreciate my gear research...
A scan through the Kiwara RNS was quite interesting. The price of copper was much lower at the time but the resource estimate when they sold it was interesting as was the investment of $15m to help it progress.
https://www.investegate.co.uk/Index.aspx?searchtype=3&words=KIW

Joeman,
Kalumbila (sold by Kiwara) was an AA licence. The copper price and AA exiting Zambia was their reason for relinquishing it and obviously AA didn't buy it back. A scan through some of the Kiwara RNS was quite interesting. I don't know if it was down to luck or good planning but Kalumbila appeared at a very good time for First Quantum. I'm still not convinced AA is our most likely customer.
A 7am RNS with some decent news would be good...

Hi OC,
Glad to see you are keeping up to date with the entertainment channel. You didn't start the off topic thread so don't feel too guilty.
I am unlikely to apologise to investors for pointing out the red flags when the SP was much higher and continue pointing out the issues as the investment case appears weaker. I suggest anyone invested in any CB company reviews their investment on a regular basis. If he 'surrenders' his options (ie gains the monetary benefit without putting the exercise price into the company) then they might want to consider selling. If CB tweets that a company is fully funded, surrenders his options a week later and follows that by a placing a week later then it is quite possibly a sign things aren't right. If this is followed by the loss of a mining licence (or similar event) it is probably time to protect your capital. This is not investment advice just my views on an approach to investing. This is aim so anything can (and does) happen. We could even get an RNS in the morning to state ARCM have hit over 200m of mineralisation at 0.59% copper but I think that is unlikely!

Hi Careful,
I'm fortunate in that my feet are attached to the rest of me - it definitely helps prevent me losing them :-).